AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32553932 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase
Number of subjects: 600
Study 32553932 — intervention group
Group type: COMPARATOR
Intervention: Routine pPCI
Number of subjects: 600
Study 35268018 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful eating (MIND)
Number of subjects: 99
Study 35268018 — intervention group
Group type: COMPARATOR
Intervention: Eating without distractions (CON-D)
Number of subjects: 99
Study 35268018 — intervention group
Group type: COMPARATOR
Intervention: No instructions (CON-I)
Number of subjects: 99
Study 33966699 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasound (DTF-DB and DE-DB measurements)
Number of subjects: 0
Study 33310801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose antihypertensive monotherapy
Number of subjects: 2423
Study 33310801 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose monotherapy (defined daily dose: 0.5 units)
Number of subjects: 2423
Study 36100413 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glucose solution
Number of subjects: 65
Study 36100413 — intervention group
Group type: COMPARATOR
Intervention: 50% glucose solution
Number of subjects: 65
Study 34134574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with TPF induction chemotherapy (5-fluorouracil, cisplatin, and docetaxel)
Number of subjects: 120
Study 34134574 — intervention group
Group type: COMPARATOR
Intervention: TPF induction chemotherapy alone
Number of subjects: 120
Study 34134574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with TPF induction chemotherapy
Number of subjects: 120
Study 32028982 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (SM)
Number of subjects: 50
Study 32028982 — intervention group
Group type: COMPARATOR
Intervention: Sham Procedure
Number of subjects: 50
Study 32533314 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol
Number of subjects: 70
Study 32533314 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 35538465 — intervention group
Group type: EXPERIMENTAL
Intervention: Group/Individual CRAFT
Number of subjects: 249
Study 35538465 — intervention group
Group type: COMPARATOR
Intervention: Self-administered CRAFT (control group)
Number of subjects: 249
Study 34866887 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Pain Prevention Program (SPPP) with one instruction session and a refresher session 4 weeks later with a physical therapist
Number of subjects: 100
Study 34866887 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder Pain Prevention Program (SPPP) with a 4-week series of 2-hour group classes taught by a physical therapist and peer mentor
Number of subjects: 100
Study 34866887 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical controls from a 3-year observational study)
Number of subjects: 100
Study 34866887 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups
Number of subjects: 100
Study 34971475 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy at a flow rate of 30 ml/min
Number of subjects: 80
Study 34971475 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy at a flow rate of 60 ml/min
Number of subjects: 80
Study 34154520 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners for Change Outcome Management System (PCOMS)
Number of subjects: 100
Study 34154520 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 100
Study 32619832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemoradiotherapy (fluorouracil and oxaliplatin)
Number of subjects: 52
Study 36054737 — intervention group
Group type: COMPARATOR
Intervention: Mealtime ultra-rapid lispro (URLi)
Number of subjects: 716
Study 36054737 — intervention group
Group type: COMPARATOR
Intervention: Postmeal ultra-rapid lispro (URLi)
Number of subjects: 716
Study 36054737 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro
Number of subjects: 716
Study 34360315 — intervention group
Group type: EXPERIMENTAL
Intervention: ProLiSMental psychoeducational intervention (4 or 8 weekly sessions of 90 or 45 min)
Number of subjects: 38
Study 34360315 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (WLCG)
Number of subjects: 38
Study 32485323 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting programme intervention
Number of subjects: 552
Study 33242705 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative and end-of-life care education
Number of subjects: 95
Study 33242705 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching strategies
Number of subjects: 95
Study 32114728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin + Glutamine
Number of subjects: 32
Study 32114728 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 32
Study 32114728 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 32
Study 32114728 — intervention group
Group type: COMPARATOR
Intervention: Conventional Treatment
Number of subjects: 32
Study 35043556 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month continuity of care
Number of subjects: 100
Study 35043556 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing (control)
Number of subjects: 100
Study 34675886 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using IPro2 device
Number of subjects: 120
Study 34675886 — intervention group
Group type: COMPARATOR
Intervention: Oral Glucose Tolerance Test (OGTT)
Number of subjects: 120
Study 32840920 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA in situ hybridization
Number of subjects: 100
Study 32840920 — intervention group
Group type: COMPARATOR
Intervention: Control sections
Number of subjects: 100
Study 33041022 — intervention group
Group type: EXPERIMENTAL
Intervention: HYD diet (75 mg/kg Zn from HYD)
Number of subjects: 24
Study 33041022 — intervention group
Group type: COMPARATOR
Intervention: Control diet (75 mg/kg Zn from zinc sulfate)
Number of subjects: 24
Study 33041022 — intervention group
Group type: EXPERIMENTAL
Intervention: FRHYD (40% of ad libitum feed intake and HYD diet)
Number of subjects: 24
Study 33041022 — intervention group
Group type: COMPARATOR
Intervention: FRCON (40% of ad libitum feed intake and control diet)
Number of subjects: 24
Study 33041022 — intervention group
Group type: EXPERIMENTAL
Intervention: FR treatments (40% of ad libitum feed intake)
Number of subjects: 24
Study 33041022 — intervention group
Group type: COMPARATOR
Intervention: AL treatments (ad libitum fed)
Number of subjects: 24
Study 35332591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy with birch and 5-grass allergen extracts (10,000 SQ units/ml, ALK-Abelló)
Number of subjects: 0
Study 35332591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy with birch and placebo
Number of subjects: 0
Study 35332591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy with 5-grass and placebo
Number of subjects: 0
Study 35332591 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 33723066 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel administration
Number of subjects: 60
Study 33723066 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel administration
Number of subjects: 60
Study 32171667 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) - 90 min exposure to 100% O2 at 2 atmospheres absolute, daily for 5 days a week for 4 weeks before surgery and 10 additional sessions after first-stage surgery
Number of subjects: 21
Study 32171667 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical procedure without HBOT (Control)
Number of subjects: 21
Study 35948268 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 long‐chain polyunsaturated fatty acid supplementation (4.2 g per day)
Number of subjects: 28
Study 35948268 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 28
Study 33826132 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1598
Study 33826132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1598
Study 33826132 — intervention group
Group type: EXPERIMENTAL
Intervention: All-bari-2-mg-AD
Number of subjects: 1598
Study 33351042 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (n=80; mean dose 161 μg/d)
Number of subjects: 160
Study 33351042 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol (n=80; mean dose 3.2 mg/d)
Number of subjects: 160
Study 33351042 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 160
Study 33351042 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 160
Study 34933097 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 299
Study 34933097 — intervention group
Group type: COMPARATOR
Intervention: Control (non-obese patients)
Number of subjects: 299
Study 32311675 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally heated jacket (HEAT)
Number of subjects: 10
Study 32311675 — intervention group
Group type: COMPARATOR
Intervention: Standardized tracksuit top (CON)
Number of subjects: 10
Study 32419128 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual chest compression (CC)
Number of subjects: 35
Study 32419128 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression with CPRMeter
Number of subjects: 35
Study 32419128 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression with LifeLine ARM device
Number of subjects: 35
Study 34614363 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium bicarbonate
Number of subjects: 170
Study 34614363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 32694183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal noninvasive ventilation
Number of subjects: 14
Study 32694183 — intervention group
Group type: COMPARATOR
Intervention: Long-term oxygen therapy (nasal cannula)
Number of subjects: 14
Study 35607776 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroEPO (nasally administered recombinant EPO)
Number of subjects: 34
Study 35607776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 35607776 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroEPO
Number of subjects: 34
Study 32876054 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (ELC)
Number of subjects: 176
Study 32876054 — intervention group
Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy (DLC)
Number of subjects: 176
Study 32876054 — intervention group
Group type: COMPARATOR
Intervention: Comparison of complications
Number of subjects: 176
Study 32876054 — intervention group
Group type: COMPARATOR
Intervention: Comparison of hospital stay and total costs
Number of subjects: 176
Study 35208601 — intervention group
Group type: EXPERIMENTAL
Intervention: Needleless Jet Anesthesia (JA)
Number of subjects: 30
Study 35208601 — intervention group
Group type: COMPARATOR
Intervention: Conventional Syringe (CS)
Number of subjects: 30
Study 32049937 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly teriparatide (WT) from 1 week to 6 months postoperatively
Number of subjects: 104
Study 32049937 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonate (BP)
Number of subjects: 104
Study 32049937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone contact status (BC+)
Number of subjects: 104
Study 32049937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone contact status (BC-)
Number of subjects: 104
Study 33664159 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS) gait training
Number of subjects: 2
Study 32541882 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention involving regular telephone calls and home visits
Number of subjects: 204
Study 33738492 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab + LEF
Number of subjects: 140
Study 33738492 — intervention group
Group type: COMPARATOR
Intervention: Placebo + LEF
Number of subjects: 140
Study 32236402 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention + placebo
Number of subjects: 269
Study 32236402 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention + n-3 PUFA
Number of subjects: 269
Study 32236402 — intervention group
Group type: COMPARATOR
Intervention: n-3 PUFA supplementation alone
Number of subjects: 269
Study 36229121 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIT-CU
Number of subjects: 43
Study 36229121 — intervention group
Group type: COMPARATOR
Intervention: Standard PCIT
Number of subjects: 43
Study 35395021 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referred message
Number of subjects: 264
Study 35395021 — intervention group
Group type: COMPARATOR
Intervention: Family-referred message
Number of subjects: 264
Study 34476612 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 100
Study 34476612 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine
Number of subjects: 100
Study 34476612 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in core temperature at 25 and 30 min after SA
Number of subjects: 100
Study 34476612 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 100
Study 33789028 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate‐Amodiaquine (AS+AQ)
Number of subjects: 712
Study 33789028 — intervention group
Group type: COMPARATOR
Intervention: Artemether‐Lumefantrine (AL)
Number of subjects: 712
Study 35465375 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroxylenol antiseptic soap bath before operation
Number of subjects: 96
Study 35465375 — intervention group
Group type: COMPARATOR
Intervention: Standard ward pre-operative preparation procedures
Number of subjects: 96
Study 35465375 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroxylenol antiseptic soap bath
Number of subjects: 96
Study 32032738 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS targeting the auditory cortex
Number of subjects: 22
Study 32032738 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study 35613009 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 120
Study 35613009 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 120
Study 33055078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg intravenous, two infusions 4 weeks apart)
Number of subjects: 91
Study 33055078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 33055078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 91
Study 32602828 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with a tumor radiation-absorbed dose greater than or equal to 100 Gy (n = 67)
Number of subjects: 121
Study 32602828 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with optimal agreement (n = 24)
Number of subjects: 121
Study 32602828 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE)
Number of subjects: 121
Study 32602828 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial radioembolization (TARE) with tumor radiation-absorbed dose greater than or equal to 100 Gy and optimal agreement
Number of subjects: 121
Study 32602828 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 121
Study 34157632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 1500 mg
Number of subjects: 29
Study 34157632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 33395597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal opioid overdose
Number of subjects: 8370
Study 32567708 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sessions of ISTDP with the use of challenge
Number of subjects: 42
Study 32567708 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sessions of ISTDP without the use of challenge
Number of subjects: 42
Study 32567708 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 42
Study 33864548 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) - 10 sessions (n=31)
Number of subjects: 64
Study 33864548 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) (n=33)
Number of subjects: 64
Study 33400330 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 383
Study 32271271 — intervention group
Group type: EXPERIMENTAL
Intervention: Clareon IOL
Number of subjects: 139
Study 32271271 — intervention group
Group type: COMPARATOR
Intervention: Tecnis PCB00 IOL
Number of subjects: 139
Study 36006808 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred stenting (n = 594)
Number of subjects: 1205
Study 32915043 — intervention group
Group type: EXPERIMENTAL
Intervention: hypCPT (cognitive processing therapy + hypnosis)
Number of subjects: 45
Study 32915043 — intervention group
Group type: COMPARATOR
Intervention: ssmCPT (sleep and psychiatric symptom monitoring plus cognitive processing therapy)
Number of subjects: 45
Study 35294683 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps to Success
Number of subjects: 594
Study 35294683 — intervention group
Group type: COMPARATOR
Intervention: Control group (existing home visiting program)
Number of subjects: 594
Study 32432718 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free, biolimus A9-eluting drug-coated stent with 1-month dual antiplatelet therapy
Number of subjects: 2432
Study 32432718 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 2432
Study 32894418 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral stress management intervention
Number of subjects: 99
Study 32894418 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation control group
Number of subjects: 99
Study 32778489 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% polidocanol + 70% hypertonic glucose (HG)
Number of subjects: 115
Study 32778489 — intervention group
Group type: COMPARATOR
Intervention: 75% hypertonic glucose (HG) alone
Number of subjects: 115
Study 35750555 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 92
Study 35750555 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 92
Study 33508626 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D digital measurement using a handheld scanner
Number of subjects: 100
Study 33508626 — intervention group
Group type: COMPARATOR
Intervention: Traditional measurement using electronic digital caliper
Number of subjects: 100
Study 33508626 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D digital measurement
Number of subjects: 100
Study 33508626 — intervention group
Group type: COMPARATOR
Intervention: Traditional measurement
Number of subjects: 100
Study 34984839 — intervention group
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection (RCI, 80 U)
Number of subjects: 35
Study 34984839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 32979620 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) prior to TBLB
Number of subjects: 50
Study 32979620 — intervention group
Group type: COMPARATOR
Intervention: Placebo prior to TBLB
Number of subjects: 50
Study 32384055 — intervention group
Group type: EXPERIMENTAL
Intervention: MYLO (Manage Your Life Online)
Number of subjects: 112
Study 32384055 — intervention group
Group type: COMPARATOR
Intervention: ELIZA
Number of subjects: 112
Study 32384055 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MYLO and ELIZA
Number of subjects: 112
Study 32384055 — intervention group
Group type: EXPERIMENTAL
Intervention: MYLO
Number of subjects: 112
Study 33073298 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue stem cell-derived exosomes gel
Number of subjects: 25
Study 33073298 — intervention group
Group type: COMPARATOR
Intervention: Control gel
Number of subjects: 25
Study 34550563 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2 µg kg-1 h-1)
Number of subjects: 80
Study 34550563 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (0.5 ml kg-1 h-1)
Number of subjects: 80
Study 34323574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Motivational Interviewing (TMI)
Number of subjects: 19
Study 34323574 — intervention group
Group type: COMPARATOR
Intervention: Services as usual (Control)
Number of subjects: 19
Study 33176942 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL System (JS) in four flavors (Virginia Tobacco, Mango, Mint, Creme, [5.0 % nicotine; 59 mg/mL])
Number of subjects: 66
Study 33176942 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL System (JS)
Number of subjects: 66
Study 33176942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mint and Mango JS flavors
Number of subjects: 66
Study 35927518 — intervention group
Group type: EXPERIMENTAL
Intervention: Burosumab
Number of subjects: 134
Study 35927518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 36410666 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily TPTD (20 μg daily)
Number of subjects: 86
Study 36410666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic TPTD (20 μg daily for 3 months followed by 3 months off)
Number of subjects: 86
Study 33879849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (n = 13)
Number of subjects: 89
Study 33879849 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 89
Study 33879849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive infants (n = 36)
Number of subjects: 89
Study 33879849 — intervention group
Group type: COMPARATOR
Intervention: Non-hypotensive infants (n = 53)
Number of subjects: 89
Study 36432461 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily walnut consumption
Number of subjects: 0
Study 36432461 — intervention group
Group type: COMPARATOR
Intervention: Academic stress
Number of subjects: 0
Study 33090462 — intervention group
Group type: EXPERIMENTAL
Intervention: +EBR (10 nM EBR)
Number of subjects: 0
Study 33090462 — intervention group
Group type: COMPARATOR
Intervention: -EBR (0 nM EBR)
Number of subjects: 0
Study 32404535 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality with regular training (VRRT)
Number of subjects: 0